Angela W. Chen

Angela W. Chen

Auto-generated profile, based on publicly available information

Angela W. Chen

Department of Health Systems and Population Health, University of Washington School of Public Health, Seattle, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Birth
Verified
Journal Article
Closed access
ACAngela W. Chen
Angela W. Chen
MHMaiah J. Hall
Maiah J. Hall
MAMolly R. Altman
Molly R. Altman

26 June 2025 in American Journal of Public Health
Verified
Journal Article
Closed access
ACAngela W. Chen
Angela W. Chen
TATaryn L. Amberson
Taryn L. Amberson
HAHarriet Fridah Adhiambo
Harriet Fridah Adhiambo
BWBradley H. Wagenaar
Bradley H. Wagenaar
Objectives. To determine if Medicaid expansion was associated with increased human papillomavirus (HPV) vaccination among adolescents in the United States. Methods. We conducted a quasi-experimental study using generalized difference-in-differences on National Immunization Survey‒Teen data from 2011 to 2022 among adolescents aged 13 to 17 years, comparing HPV vaccination in Medicaid expansion states to nonexpansion states by sex and race/ethnicity subgroups. Results. There was a significant 10.1-percentage-point increase in HPV vaccination among male adolescents in expansion states (95% confidence interval [CI] = 8.9, 12.4; P < .001). Significant increases in HPV vaccination were observed among all male racial subgroups, with largest effects among Black, Latino, and other or multiple races. No effect was observed among female adolescents or any racial subgroup. Conclusions. Medicaid expansion was associated with significant increases in HPV vaccination among male adolescents, with no effects observed among female adolescents. All male race/ethnicity subgroups showed increases, with Black, Latino, and other or multiple race/ethnicity male adolescents having the largest effect. Public Health Implications. Medicaid expansion is an appropriate and effective policy for increasing HPV vaccination uptake for priority populations, including historically marginalized racial/ethnic groups and male adolescents. ( Am J Public Health. Published online ahead of print June 26, 2025:e1–e9. https://doi.org/10.2105/AJPH.2025.308165 )

13 September 2024 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
ACAngela W Chen
Angela W Chen
PFPaul A Fishman
Paul A Fishman
Introduction: Smoking is the leading preventable cause of death and disability in the United States. A 2019 randomized controlled trial found e-cigarettes are more effective than nicotine replacement therapy (NRT) in achieving abstinence when both are combined with behavioral counseling. Few cost-effectiveness studies have been performed regarding e-cigarettes as an adjunct to cessation efforts, and none in a U.S. context. This study evaluated the cost-effectiveness of e-cigarettes compared to NRT, both with counseling, and as cessation aids for Medicaid smokers in California. Aims and Methods: A cost-effectiveness analysis from a U.S. societal perspective comparing e-cigarettes with NRT was constructed. Using a lifetime horizon, smokers were followed to different health states to their expected lifespan. Costs were expressed in 2020 U.S. dollars and health outcomes in quality-adjusted life years (QALY). All costs and outcomes were discounted at a 3% annual rate and model findings were assessed with a series of sensitivity analyses. Results: Using U.S. willingness-to-pay thresholds, e-cigarettes were more cost-effective than NRT, with an incremental cost-effectiveness ratio of $11 454 per additional QALY gained over smokers’ lifetimes. Results were sensitive to smokers’ healthcare costs, model start ages, discount rates, and QALY weights. Conclusions: E-cigarettes used as a cessation treatment by smokers are more cost-effective relative to NRT. However, e-cigarettes as a treatment are currently unapproved by the Food and Drug Administration (FDA). Despite the lack of FDA approval, e-cigarettes are a popular choice among smokers trying to quit. Policymakers should consider whether providing financial support for e-cigarettes as a harm reduction strategy is worth pursuing. Implications: As e-cigarettes grow in popularity and are an increasingly preferred choice of smoking cessation aid among smokers attempting to quit, it is important to examine the inclusion of these products in tobacco policy, research, and practice. Several countries have now adopted or are in the process of adopting e-cigarettes as a medically licensed and regulated smoking cessation aid. Future smoking cessation strategies by U.S. policymakers may consider the adoption of e-cigarettes as a cost-effective harm reduction tool for use by current smokers seeking to quit.

29 October 2026 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Closed access
PDF file
ACAngela W. Chen
Angela W. Chen
DTDavid T. Takeuchi
David T. Takeuchi
IRIsaac C. Rhew
Isaac C. Rhew

26 May 2026 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Closed access
RHRaymond Hsu
Raymond Hsu
ACAngela W. Chen
Angela W. Chen
KMKris Pui Kwan Ma
Kris Pui Kwan Ma
EYEugene Yang
Eugene Yang